LivaNova (NASDAQ: LIVN) — Perfil da empresa, notícias e dados financeiros
LivaNova is a medical technology company developing solutions in cardiovascular and neuromodulation to enhance patient outcomes.
LivaNova
LivaNova (NASDAQ:LIVN) is a global medical technology company focused on developing innovative solutions that improve patient outcomes and enhance lives. The company operates two primary business segments: Cardiovascular and Neuromodulation. In the cardiovascular realm, LivaNova is dedicated to advancing technology for cardiac surgery, including heart valve therapy, and cardiopulmonary solutions. On the neuromodulation front, the company is a pioneer in offering devices designed to treat epilepsy and depression, aiming to address some of the most challenging areas of unmet medical needs. With a commitment to clinical excellence and innovation, LivaNova's projects and objectives are centered around transforming the standard of care for patients around the world, driving sustainable growth, and extending its reach into new markets to improve more lives with their medical technologies.
Resumo
Operações
Produtos e/ou serviços de LivaNova
- Vagus Nerve Stimulation (VNS) Therapy Systems for drug-resistant epilepsy and treatment-resistant depression, offering a unique non-pharmacological treatment option.
- Perceval sutureless aortic valve, providing a less invasive option for surgical aortic valve replacement in patients with aortic valve disease.
- SenTiva generator and VNS Therapy Programming System, an advanced option for managing seizures in drug-resistant epilepsy, allowing for tailored treatment.
- LifeSPARC advanced circulatory support system, designed for rapid deployment in patients needing circulatory support during cardiac procedures or acute heart failure.
- Solox cardiovascular oxygenator, a key component in cardiopulmonary bypass surgery, supporting patients' lungs and heart during complex cardiac surgeries.
- Membrane oxygenators, which play a crucial role in extracorporeal membrane oxygenation (ECMO) for patients with life-threatening heart and lung conditions.
equipe executiva do LivaNova
- Vladimir A. MakatsariaCEO & Director
- Alex ShvartsburgChief Financial Officer
- Natalia Sergeyevna KozminaChief Human Resources Officer
- Ahmet TezelChief Innovation Officer
- Lindsey LittleVP & Chief Accounting Officer
- Briana GotlinVice President of Investor Relations
- Anne M. LiddyChief Legal Officer
- Deanna WilkeVice President of Corporate Communications
- Philip KowalczykChief Strategy & Corporate Development Officer
- Paul R. BuckmanPresident of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement
Principais indicadores financeiros
Resultados divulgados pela LivaNova , em USD.
- Cap. de mercado
- 4,4 bi
- Receita (TTM)
- 1,5 bi
- P/L
- 23.8
- LPA (diluído, TTM)
- 3.4
- Dividend yield
- —
- Margem de lucro
- 12.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,4 bi | 199,4 mi | -242,5 mi | |
| 1,3 bi | 129,1 mi | 63,2 mi | |
| 1,2 bi | -68,5 mi | 17,5 mi | |
| 1 bi | -76,8 mi | -86,2 mi |